Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Mary Jenkins - Senior Manager of Investor Relations Doug Ingram - President & Chief Executive Officer Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer and Head of R&D Dallan Murray - Senior Vice President & Chief Customer Officer Ian Estepan - Executive Vice President & Chief Financial Officer Gilmore O'Neill - Chief Medical Officer & Executive Vice President Conf ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 For the transition period from to Commission file number 001-14895 SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (I.R.S. Employer Identification No.) Regi ...

| --- | --- | --- | --- | |-----------------------------------------------------------------|-------|--------------------------------------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | SRP-9001: New Clinical Data and Integrated Analysis | | | | | | | | | | DOUG INGRAM President and Chief Executive Officer | | | | | LOUISE RODINO-KLAPAC, PH.D. | | | | | Executive Vice President, Head of R&D, Chief Scientific Officer | | | | | July 6, 2022 8:30 a.m. ET | | | | | | | ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Mary Jenkins - Senior Manager of Investor Relations Dallan Murray - Senior Vice President & Chief Customer Officer Doug Ingram - President & Chief Executive Officer Ian Estepan - Executive Vice President & Chief Financial Officer Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer and Head of R&D Conference Call Participants Colin Bristow - UBS Brian Abrahams - RBC Capi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other juri ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2021 Earnings Conference Call March 1, 2022 4:30 PM ET Company Participants Mary Jenkins - Senior Manager of Investor Relations Doug Ingram - President & Chief Executive Officer Ian Estepan - Executive Vice President & Chief Financial Officer Dallan Murray - Senior Vice President & Chief Commercial Officer Gilmore O'Neill - Executive Vice President of R&D & Chief Medical Officer Louise Rodino-Klapac - Executive Vice President & Chief Scientific Officer Conference ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number : 001-14895 Sarepta Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other jurisdi ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2021 Earnings Conference Call November 3, 2021 4:30 PM ET Company Participants Mary Jenkins - Senior Manager of Investor Relations Doug Ingram - President & Chief Executive Officer Ian Estepan - Executive Vice President & Chief Financial Officer Dallan Murray - Senior Vice President & Chief Commercial Officer Gilmore O'Neill - Executive Vice President of R&D & Chief Medical Officer Louise Rodino-Klapac - Executive Vice President & Chief Scientific Officer Conferen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other ...

Summary of Sarepta Therapeutics, Inc. Conference Call Company Overview - **Company**: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - **Industry**: Biotechnology, specifically focusing on therapies for Duchenne muscular dystrophy (DMD) Key Highlights 1. **Progress on SRP-5051**: The company is ahead of schedule in its clinical trials, aiming to dose the first patient in Q4 2021, earlier than initially planned [2][3] 2. **MOMENTUM Trial**: The pivotal trial for accelerated approval is referred to as Part B of the MOMENTUM study, with promising initial data showing significant exon skipping and dystrophin production compared to existing therapies [4][5] 3. **Dystrophin Production**: Initial results indicated an exon skipping rate 18 times greater than eteplirsen, with a projected dystrophin level exceeding 10% after one year of treatment [4][5][16] 4. **FDA Interaction**: The company has established a positive relationship with the FDA's Neurology division, which has experience with DMD, and has received guidance on using dystrophin as a surrogate endpoint for accelerated approval [7][9] 5. **Safety Profile**: Concerns regarding hypomagnesemia have been addressed, with the company confident that it can be managed through oral supplements [18][20] 6. **PPMO Platform**: The PPMO technology has the potential to treat approximately 80% of DMD patients, with ongoing efforts to develop therapies for rare mutations [26][39] 7. **Gene Therapy Synergy**: The company is exploring the potential for synergistic effects between its PPMO platform and gene therapy, SRP-9001, to provide comprehensive treatment options for DMD [28][29] 8. **Competitive Advantage**: Sarepta claims to have unique results in human trials with its PMO and PPMO therapies, setting it apart from competitors [32][34] Additional Insights 1. **Patient Compliance**: The company reports a compliance rate of over 90% for its therapies, indicating strong patient adherence despite the challenges posed by the pandemic [13] 2. **Future Directions**: The company plans to expand its research into other neuromuscular diseases and is focused on developing additional constructs for other skip amenable mutations [39][38] 3. **Upcoming Trials**: The company is preparing for the launch of the 301 study, which will be a double-blind, placebo-controlled trial with a primary endpoint of functional output [48][50] This summary encapsulates the key points discussed during the conference call, highlighting the company's advancements, regulatory interactions, and future plans in the biotechnology sector focused on DMD.